13 results about "Equine Encephalitis" patented technology

This disclosure relates to certain N4-hydroxycytidine derivatives, pharmaceutical compositions, and methods related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of viral infections, such as Eastern, Western, and Venezuelan Equine Encephalitis (EEE, WEE and VEE, respectively), Chikungunya fever (CHIK), Ebola, Influenza, RSV, and Zika virus infection with the disclosed compounds.

Provided herein are methods and compositions related to the finding that specific mutations in nonstructural proteins of self-replicating RNA molecules including RNA replicons, such as Sindbis RNA replicons or Venezuelan equine encephalitis (VEE) replicons, can stabilize the longevity of the RNA replicon and can stabilize the expression of the cargo proteins encoded by the self-replicating RNA molecule or RNA replicon. Also disclosed herein are compositions and methods directed to the discovery that certain viral proteins, including viral proteins that repress internal cellular innate immunity, can stabilize the payload expression and replication of the replicons. Technologies provided herein provide stabilization mechanisms that can improve vaccines, gene therapies, and / or other gene delivery methods.

The present disclosure is concerned with substituted tetrahydrobenzothiophene and tetrahydropyridothiophene compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds in the treatment of viral infections due to a Flavi virus (e.g, yellow fever, Japanese encephalitis, dengue (DENV), West Nile virus (WNV), zika (ZIKV), tick-bome encephalitis virus. Kunjin virus. Murray Valley encephalitis, St Louis encephalitis, Omsk hemorrhagic fever virus, bovine viral diarrhea virus, Hepatitis C virus) or an Alphavirus (e.g., Venezeulan equine encephalitis virus, chikungunya virus (CHIKV), Ross River virus, Mayaro virus, Sindbis virus). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Disclosed are halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of viral infections. Such viral infections can include enterovirus, tongaviridae, bunyaviridae, arenaviridae, coronaviridae, flaviviridae, picornaviridae, Eastern, Western, and Venezuelan Equine Encephalitis (EEE, WEE and VEE, respectively), Chikungunya fever (CHIK), Ebola, Influenza, RSV, and Zika virus infections.

This disclosure relates to certain N4-hydroxycytidine derivatives, pharmaceutical compositions, and methods related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of viral infections, such as Eastern, Western, and Venezuelan Equine Encephalitis (EEE, WEE and VEE, respectively), Chikungunya fever (CHIK), Ebola, Influenza, RSV, and Zika virus infection with the disclosed compounds.

To provide pharmaceutical compositions and methods for the treatment of viral infections.SOLUTION: Halogen-containing nucleotide and nucleoside therapeutic compositions and uses related thereto are disclosed. In certain embodiments, the disclosure relates to the treatment or prevention of viral infections. Such viral infections may include togaviridae, bunyaviridae, arenaviridae, coronaviridae, flaviviridae, picornaviridae, eastern equine encephalitis, western equine encephalitis, and Venezuelan equine encephalitis (EEE, WEE, and VEE, respectively), chikungunya (CHIK), Ebola, flu, RSV, and Zika virus infections.SELECTED DRAWING: Figure 1

Halogen-containing nucleotide and nucleoside therapeutic compositions and related uses thereof are disclosed. In certain embodiments, the disclosure relates to the treatment or prevention of viral infections. Such viral infections may comprise a tapiviridae, a bunyaviridae, an arenaviridae, a coronaviridae, a flaviviridae, a picornaviridae, eastern equine encephalitis, western equine encephalitis, and Venezuela equine encephalitis (EEE, WEE, and VEE, respectively), Chikungunya fever (CHIK), Ebola, influenza, RSV, and Zika viral infections.

The present disclosure relates to the field of molecular virology, and particularly relates to nucleic acid molecules encoding a modified equine encephalitis virus viral genome or self-replicating RNA (srRNA) construct, pharmaceutical compositions containing the same, and the use of such nucleic acid molecules and compositions for production of desired products in cell cultures or in a living body. Also provided are methods for eliciting an immune response in a subject in need thereof, as well as methods for preventing and / or treating cancer.

Halogen-containing nucleotide and nucleoside therapeutic compositions and related uses thereof are disclosed. In certain embodiments, the disclosure relates to the treatment or prevention of viral infections. Such viral infections may include enterovirus, tapiviridae, bunyaviridae, arenaviridae, coronaviridae, flaviviridae, picornaviridae, eastern equine encephalitis, western equine encephalitis, and Venezuela equine encephalitis (EEE, WEE, and VEE, respectively), Chikungunya fever (CHIK), Ebola, influenza, RSV, and Zika virus infections.

Disclosed are purine nucleotide and nucleoside therapeutic compositions therapeutic compositions and uses related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of viral infections. Such viral infections can include enterovirus, tongaviridae, bunyaviridae, arenaviridae, coronaviridae, flaviviridae, picornaviridae, Eastern, Western, and Venezuelan Equine Encephalitis (EEE, WEE and VEE, respectively), Chikungunya fever (CHIK), Ebola, Influenza, RSV, and Zika virus infections.

The present disclosure is directed to antibodies binding to and neutralizing Venezuelan Equine Encephalitis Vims (VEEV) and methods for use thereof.

To provide a novel treatment for viral infections. [Solution] Halogen-containing nucleotide and nucleoside therapeutic compositions and related uses are disclosed. In certain embodiments, the disclosure relates to the treatment or prevention of viral infections. Such viral infections may include Togaviridae, Bunyaviridae, Arenaviridae, Coronaviridae, Flaviviridae, Picornaviridae, Eastern equine encephalitis, Western equine encephalitis, and Venezuelan equine encephalitis (EEE, WEE, and VEE, respectively), Chikungunya fever (CHIK), Ebola, influenza, RSV, and Zika virus infection. In exemplary embodiments, the compound is selected from the following: TIFF2026062641000590.tif42170

To provide specific N4-hydroxycytidine derivatives, pharmaceutical compositions, and related methods. [Solution] In certain embodiments, this disclosure relates to the treatment or prevention of viral infections such as Eastern equine encephalitis, Western equine encephalitis, and Venezuelan equine encephalitis (EEE, WEE, and VEE, respectively), Chikungunya fever (CHIK), Ebola, influenza, RSV, and Zika virus infection, by the compounds disclosed. In certain embodiments, this disclosure intends to provide derivatives of the compounds disclosed herein, such as compounds containing one or more of the same or different substituents.